SKTG — what changed in the latest 10-Q
A section-by-section comparison of SKTG's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-20 vs the prior 10-Q · 2025-11-19
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +145 | −162 | ~13 | 24 |
| Market risk (Item 3) | Text added/removed | +22 | −50 | ~18 | 20 |
| Controls & procedures | Text added/removed | +22 | −50 | ~18 | 20 |
| Legal proceedings | Text added/removed | +22 | −50 | ~18 | 20 |
| Risk factors | Text added/removed | +22 | −50 | ~18 | 20 |
| Other information | Text added/removed | +22 | −50 | ~17 | 20 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-20
Management Discussion & Analysis of Financial Condition & Results of Operations
SkyTech Orion Global Corp. (the “Company”) is a U.S.-based corporation, with subsidiaries in Israel, focused on building end-to-end drone solutions from innovative modular drone platforms to large-scale production.
The Company is building a multi-layered industrial and modular infrastructure focused on the drone and defense sectors, combining proprietary in-house development, OEM capabilities, strategic partnerships, and targeted mergers and acquisitions (M&A). This structure is designed to address the growing…
The core of the Company’s technology is a proprietary modular architectural approach based on the separation between intelligent core systems and the drone’s airframe, power systems, sensors, communications, and payload components.
This approach enables the use of a standardized core unit, the Smart Core Unit™, which integrates with a wide range of airframes, propulsion systems, sensors, and payloads, thereby enabling high flexibility, shortened development cycles, and efficient scalability across multiple platforms and use ca…
Text removed vs the prior filing · source: 10-Q · 2025-11-19
Citrine Global Corp. (DBA SkyTech Orion Global Corp.) reports that the Company has formally changed its corporate name in the State of Delaware to SkyTech Orion Global Corp. and is currently completing the corresponding name-change procedures with FINRA.
As previously described, during 2024–2025 we emerged from a challenging period for the Company, for Israel, and for the global environment in which we operate, following the events of October 7, 2023 and the resulting war, which significantly affected the Israeli economy and the activities of our su…
Based on this assessment, we made a strategic decision not merely to continue our operations, but to transform the Company’s vision, structure, and activities to align with the developing global defense, unmanned systems, and advanced drone markets. This process resulted in the Company’s transition …
We developed the SkyTech Replicator™, a modular, multi-mission drone platform based on a single Core Unit and our proprietary Click & Fly™ mechanism, enabling rapid mission reconfiguration and real-time adaptation for defense and dual-use applications. In parallel, we filed multiple patent applicati…
To support industrial scalability, we created the Replication Manufacturing Method, enabling rapid replication of production lines using advanced manufacturing and 3D-printing technologies, in collaboration with Stratasys, a global leader in additive manufacturing. Furthermore, our Israeli subsidiar…
Market risk (Item 3)
Text added vs the prior filing · source: 10-Q · 2026-05-20
Basic weighted average number of shares of common stock outstanding 1,247,855,009 1,044,074,409
Common stock Additional paid-in Stock to be Accumulated Accumulated
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2026:
Common stock Additional paid-in Stock to be Accumulated Accumulated
Accounts payable and accrued expenses – related parties 189 176
Text removed vs the prior filing · source: 10-Q · 2025-11-19
Fair value measurement of the IBOT options and impairment of Nanomedic investments (432) (747) - -
The accompanying notes are an integral part of the condensed consolidated financial statements.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT
(U.S. dollars in thousands, except share and per share data)
Common stock Additional paid-in Stock to be Accumulated Accumulated other comprehensive Total stockholders’
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-05-20
Basic weighted average number of shares of common stock outstanding 1,247,855,009 1,044,074,409
Common stock Additional paid-in Stock to be Accumulated Accumulated
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2026:
Common stock Additional paid-in Stock to be Accumulated Accumulated
Accounts payable and accrued expenses – related parties 189 176
Text removed vs the prior filing · source: 10-Q · 2025-11-19
Fair value measurement of the IBOT options and impairment of Nanomedic investments (432) (747) - -
The accompanying notes are an integral part of the condensed consolidated financial statements.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT
(U.S. dollars in thousands, except share and per share data)
Common stock Additional paid-in Stock to be Accumulated Accumulated other comprehensive Total stockholders’
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-05-20
Basic weighted average number of shares of common stock outstanding 1,247,855,009 1,044,074,409
Common stock Additional paid-in Stock to be Accumulated Accumulated
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2026:
Common stock Additional paid-in Stock to be Accumulated Accumulated
Accounts payable and accrued expenses – related parties 189 176
Text removed vs the prior filing · source: 10-Q · 2025-11-19
Fair value measurement of the IBOT options and impairment of Nanomedic investments (432) (747) - -
The accompanying notes are an integral part of the condensed consolidated financial statements.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT
(U.S. dollars in thousands, except share and per share data)
Common stock Additional paid-in Stock to be Accumulated Accumulated other comprehensive Total stockholders’
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-05-20
Basic weighted average number of shares of common stock outstanding 1,247,855,009 1,044,074,409
Common stock Additional paid-in Stock to be Accumulated Accumulated
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2026:
Common stock Additional paid-in Stock to be Accumulated Accumulated
Accounts payable and accrued expenses – related parties 189 176
Text removed vs the prior filing · source: 10-Q · 2025-11-19
Fair value measurement of the IBOT options and impairment of Nanomedic investments (432) (747) - -
The accompanying notes are an integral part of the condensed consolidated financial statements.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT
(U.S. dollars in thousands, except share and per share data)
Common stock Additional paid-in Stock to be Accumulated Accumulated other comprehensive Total stockholders’
Other information
Text added vs the prior filing · source: 10-Q · 2026-05-20
Basic weighted average number of shares of common stock outstanding 1,247,855,009 1,044,074,409
Common stock Additional paid-in Stock to be Accumulated Accumulated
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2026:
Common stock Additional paid-in Stock to be Accumulated Accumulated
Accounts payable and accrued expenses – related parties 189 176
Text removed vs the prior filing · source: 10-Q · 2025-11-19
Fair value measurement of the IBOT options and impairment of Nanomedic investments (432) (747) - -
The accompanying notes are an integral part of the condensed consolidated financial statements.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT
(U.S. dollars in thousands, except share and per share data)
Common stock Additional paid-in Stock to be Accumulated Accumulated other comprehensive Total stockholders’
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice